<DOC>
	<DOC>NCT00105170</DOC>
	<brief_summary>This is a Phase I, open-label, dose-escalation study on subjects with advanced solid tumors. This is the first study of hCBE-11 in humans and is designed to determine the safety and how well patients tolerate this investigational drug. The study duration is two years with treatment visits occurring weekly for either 4 or 8 weeks, follow-up for 8 weeks and long-term follow-up contact every 3 months thereafter.</brief_summary>
	<brief_title>Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Relapsed or refractory solid tumors not curable with standard therapy. At least one measurable lesion ECOG Performance Status less than or equal to 2 Acceptable hematologic status Albumin greater than or equal to 2.5 g/dL Normal calculated glomerular filtration rate (GFR) Acceptable liver function Uncontrolled cardiac disease, angina, congestive heart failure, or myocardial infarction within 6 months prior to Study Day Known history of hepatitis B or C, or HIV infection Clinically significant effusions, including pericardial, pleural, and ascites Serious nonmalignant disease Central nervous system (CNS) metastatic involvement except where the disease has been successfully treated Investigational therapies within 4 weeks of Study Day 1 Radiation therapy of tumors to be followed for this study Chemotherapy, biologic therapy, or major surgery other than diagnostic within 4 weeks prior to Study Day 1 Current Grade 3 or 4 neurological toxicity Concurrent antineoplastic therapy and/or steroids</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Monoclonal antibody</keyword>
	<keyword>Advanced solid tumors</keyword>
	<keyword>Tumors</keyword>
	<keyword>hCBE-11</keyword>
</DOC>